Suppr超能文献

成功采用白细胞介素-1 靶向药物联合大剂量糖皮质激素治疗 Erdheim-Chester 病。

Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids.

机构信息

I. Medizinische Klinik, Universitätsmedizin Mainz, Bad Kreuznach, Germany.

出版信息

Intern Med J. 2014 Jan;44(1):90-2. doi: 10.1111/imj.12329.

Abstract

Erdheim-Chester disease (ECD) is a rare histocytic disorder. We report a case of a 45-year-old male ECD patient with severe clinical manifestation (urinary obstruction due to retroperitoneal mass with hydronephrosis, involvement of long bones) and central nervous system involvement (hemiparesis, aphasia and diabetes insipidus). Diagnosis was confirmed by typical clinical, radiological and histological findings. Under immunosuppressive therapy with prednisolone and interleukin-1A receptor antagonist (Anakinra, Kineret, Swedish Orphan Biovitrum AB, Stockholm, Sweden), a rapid improvement of the patients' symptoms and condition was observed. This is the first report of a successful combination therapy of Anakinra and glucocorticoids. Furthermore, current literature about ECD and treatment options are discussed.

摘要

厄尔-道伊病(ECD)是一种罕见的组织细胞疾病。我们报告了一例 45 岁男性 ECD 患者,其临床表现严重(腹膜后肿块伴肾积水导致的尿路梗阻、长骨受累)并伴有中枢神经系统受累(偏瘫、失语和尿崩症)。诊断依据为典型的临床、影像学和组织学发现。在泼尼松龙和白细胞介素-1A 受体拮抗剂(Anakinra,Kineret,瑞典 Orphan Biovitrum AB,斯德哥尔摩,瑞典)的免疫抑制治疗下,患者的症状和病情迅速改善。这是首例成功联合应用 Anakinra 和糖皮质激素治疗的报告。此外,还讨论了当前关于 ECD 及治疗选择的文献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验